March 2024 FDA Recall Betimol by Thea Pharma, Inc.
D-0374-2024 - Lack of Assurance of Sterility
This Class II drug recall was voluntarily initiated by Thea Pharma, Inc. on March 5, 2024 for the product Betimol. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-0374-2024
Lack of Assurance of Sterility: Out of specification for volume and compromised container closure.
03-05-2024
03-20-2024
5,476 bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Thea Pharma, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Product was distributed nationwide within the United States
06-30-2025
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Betimol (timolol ophthalmic solution) 0.5%, 15mL bottles, Rx only, Manufactured for: Thea Pharma Inc. Lexington, MA 02420, NDC 82584-002-15
Batch or Lot Expiration Information
Lot# : 435019, Exp. Date 11/2024